Search hospitals
>
Illinois
>
Ottawa
Illinois CancerCare-Ottawa Clinic
Claim this profile
Ottawa, Illinois 61350
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Pancreatic Cancer
Conducts research for Prostate Cancer
416 reported clinical trials
22 medical researchers
Summary
Illinois CancerCare-Ottawa Clinic is a medical facility located in Ottawa, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer, Prostate Cancer and other specialties. Illinois CancerCare-Ottawa Clinic is involved with conducting 416 clinical trials across 557 conditions. There are 22 research doctors associated with this hospital, such as Bryan A. Faller, John Hilton, MD, James L. Wade, and Johanne Weberpals, MD.
Area of expertise
Breast Cancer
Illinois CancerCare-Ottawa Clinic has run 121 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Illinois CancerCare-Ottawa Clinic has run 112 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Bryan A. Faller
Crossroads Cancer Center
7 years of reported clinical research
John Hilton, MD
Ottawa Hospital Research Institute
9 years of reported clinical research
James L. Wade
Decatur Memorial Hospital
4 years of reported clinical research
Johanne Weberpals, MD
The Ottawa Hospital Cancer Centre
6 years of reported clinical research
Clinical Trials running at Illinois CancerCare-Ottawa Clinic
Prostate Cancer
Lung Cancer
Breast Cancer
Breast cancer
Cancer
Bladder Cancer
Ovarian Cancer
Multiple Myeloma
Pancreatic Cancer
Kidney Cancer
Carboplatin + Cabazitaxel
for Prostate Cancer
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Chemotherapy drugs, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is often given together with chemotherapy drugs. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs and to help the chemotherapy work. Giving carboplatin with the standard of care chemotherapy drug cabazitaxel may be better at treating metastatic castrate-resistant prostate cancer.
Recruiting
2 awards
Phase 3
5 criteria
Docetaxel + Hormonal Therapy
for Prostate Cancer
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Hormone therapy for prostate cancer, also called androgen deprivation therapy (ADT), uses surgery or drugs to lower the levels of male sex hormones in a man's body. This helps slow the growth of prostate cancer. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Giving docetaxel in addition to the usual treatment of hormonal therapy and apalutamide may work better in treating patients with metastatic prostate cancer than the usual treatment alone.
Recruiting
2 awards
Phase 3
12 criteria
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting
2 awards
Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Illinois CancerCare-Ottawa Clinic?
Illinois CancerCare-Ottawa Clinic is a medical facility located in Ottawa, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer, Prostate Cancer and other specialties. Illinois CancerCare-Ottawa Clinic is involved with conducting 416 clinical trials across 557 conditions. There are 22 research doctors associated with this hospital, such as Bryan A. Faller, John Hilton, MD, James L. Wade, and Johanne Weberpals, MD.
Where is Illinois CancerCare-Ottawa Clinic located?
The Illinois CancerCare-Ottawa Clinic is located at 1200 Starfire Drive, Ottawa, IL 61350, conveniently accessible off I-80 for patients in the area.
Who should I call to ask about financial aid or insurance network?
For financial assistance and billing inquiries at Illinois CancerCare-Ottawa Clinic, patients can use the general contact number (217) 383-3311. For more detailed billing questions, the Central Business Office can be reached at (847) 585-7000. It is advisable to contact the clinic directly for specific departmental information.
What insurance does Illinois CancerCare-Ottawa Clinic accept?
The Illinois CancerCare-Ottawa Clinic accepts a wide range of insurance plans, including but not limited to Medicare, Aetna (HMO, PPO, POS), BCBS of Illinois (PPO, POS, EPO, Classic Blue HMO, HMOI, Blue Advantage HMO), Beech Street PPO, Cigna/Great West Healthcare (HMO, PPO, POS, Open Access), and United Health Care. Additionally, they accept CorVel, Coventry/First Health/Personal Care, Evolutions, Galaxy, Health Dynamics, Healthlink PPO, HFN PPO, Humana (HMO, PPO Choice POS, Choice Care Network), Multiplan, National Provider Network, PHCS, PHCS Savility PPO, PNA, Preferred Plan, Three Rivers Provider Network. It's recommended to contact the clinic directly to confirm if your specific insurance plan is accepted.
What awards or recognition has Illinois CancerCare-Ottawa Clinic received?
Illinois CancerCare-Ottawa Clinic, located in Ottawa, Illinois, is renowned for its dedication to cancer research and quality care. It has earned the Quality Oncology Practice Initiative (QOPI®) Certification, signifying its adherence to the highest national standards for outpatient hematology-oncology practices. Furthermore, the clinic is celebrated by the Alliance for Clinical Trials in Oncology for being among the top enrollers in clinical research, demonstrating its commitment to pioneering new cancer treatments through clinical trials.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.